Patent Assignment
Reel/Frame 014125/0545
Assignment of Assignor's Interest
Recorded: 2003-06-09
Received: 2003-06-12
Pages: 11
Assignor
BAYER CORPORATION
Executed: 2003-06-03
Assignee
BAYER PHARMACEUTICALS CORPORATION
400 MORGAN LANE, WEST HAVEN, CT, 06516, UNITED STATES
Covered Properties
(36)
Aryl Ureas with Angiogenisis Inhibiting Activity
Application:
10/361,858 →
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors
Application:
10/361,850 →
Aryl ureas with raf kinase and angiogenisis inhibiting activity
Application:
10/361,844 →
Aryl Ureas as Kinase Inhibitors
Application:
10/361,859 →
Rho-Kinase Inhibitors
Application:
10/349,177 →
Rho-Kinase Inhibitors
Application:
10/349,176 →
Rho-kinase inhibitors
Application:
10/339,393 →
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
Application:
10/308,187 →
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application:
10/283,248 →
Process for Preparing Quinazoline Rho-Kinase Inhibitiors and Intermediates Thereof
Application:
10/252,369 →
Inhibition of Raf Kinase Using Quinolyl, Isoquinolyl or Pyridyl Ureas
Application:
10/125,369 →
Rho-kinase inhibitors
Application:
10/103,565 →
Aryl ureas with angiogenisis inhibiting activity
Application:
60/354,950 →
Hydroxy, W-Carboxyaryl Substituted Diphenyl Ureas and Dirivatives Thereof as Raf Kinase Inhibitors
Application:
10/071,248 →
Aryl ureas as kinase inhibitors
Application:
60/354,937 →
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
Application:
60/354,935 →
Aryl ureas with RAF kinase and angiogenisis inhibiting
Application:
60/354,948 →
Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas
Application:
10/060,396 →
Rho-kinase inhibitors
Application:
60/349,986 →
Rho-kinase inhibitors
Application:
60/349,987 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application:
10/042,203 →
Rho-kinase inhibitors
Application:
60/346,628 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application:
09/889,227 →
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
Application:
60/334,609 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application:
09/993,647 →
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application:
09/948,915 →
Inhibition of p38 kinase activity by aryl ureas
Application:
09/947,761 →
Rho-Kinase inhibitors
Application:
60/315,338 →
Heteroaryl Ureas Containing Nitrogen Hetero-Atoms as P38 Kinase Inhibitors
Application:
09/838,286 →
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
Application:
60/367,376 →
Rho-kinase inhibitors
Application:
60/277,974 →
Inhibition of Raf Kinase Using Quinolyl, Isoquinolyl or Pyridyl Ureas
Application:
09/777,920 →
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
Application:
09/778,039 →
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application:
60/367,380 →
Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application:
09/758,548 →
Raf kinase inhibitors
Application:
09/755,060 →